


Claim 1-6 (cancelled).

Claim 7 (previously presented): A compound of the formula B:



R^{2'}, R^{3'}, R^{4'}, and R^{5'} are independently selected from: H; C₁-alkyl, alkenyl, alkynyl, aryl, heterocycle, -CO-NR^{6'}R^{7'} or -CO-OR^{6'}, unsubstituted or substituted with one or more of:

- 1) aryl or heterocycle, unsubstituted or substituted with:
 - a) C_{1-4} alkyl,
 - b) $(CH_2)_tOR^{6'}$,
 - c) $(CH_2)_tNR^{6'}R^{7'}$,
 - d) halogen,
- 2) C_{3-6} cycloalkyl,
- 3) $OR^{6'}$,
- 4) $SR^{6'}$, $S(O)R^{6'}$, $SO_2R^{6'}$,
- 5) $-NR^{6'}R^{7'}$,
- 6) $-NR^{6'}-CO-R^{7'}$,
- 7) $-NR^{6'}-CO-NR^{7'}R^{8'}$,

- 8) $-\text{O}-\text{CO}-\text{NR}^{6'}\text{R}^{7'}$,
- 9) $-\text{O}-\text{CO}-\text{OR}^{6'}$,
- 10) $-\text{O}-\text{NR}^{6'}\text{R}^{7'}$,
- 11) $-\text{SO}_2\text{NR}^{6'}\text{R}^{7'}$,
- 12) $-\text{NR}^{6'}-\text{SO}_2-\text{R}^{7'}$,
- 13) $-\text{CO}-\text{R}^{6'}$, or
- 14) $-\text{CO}-\text{OR}^{6'}$;

and any two of $\text{R}^{2'}$, $\text{R}^{3'}$, $\text{R}^{4'}$, and $\text{R}^{5'}$ are optionally attached to the same carbon atom;

Y is aryl, heterocycle, unsubstituted or substituted with one or more of:

- 1) C_{1-4} alkyl, unsubstituted or substituted with:
 - a) C_{1-4} alkoxy,
 - b) $\text{NR}^{6'}\text{R}^{7'}$,
 - c) C_{3-6} cycloalkyl,
 - d) aryl or heterocycle,
 - e) HO,
- 2) aryl or heterocycle,
- 3) halogen,
- 4) $\text{OR}^{6'}$,
- 5) $\text{NR}^{6'}\text{R}^{7'}$,
- 6) CN,
- 7) NO_2 , or
- 8) CF_3 ;

$\text{R}^{6'}$, $\text{R}^{7'}$ and $\text{R}^{8'}$ are independently selected from: H; C_{1-4} alkyl, C_{3-6} cycloalkyl, heterocycle, aryl, aroyl, heteroaroyl, arylsulfonyl, heteroarylsulfonyl, unsubstituted or substituted with:

- a) C_{1-4} alkoxy,
- b) aryl or heterocycle,
- c) halogen,
- d) HO,
- e) $-\text{CO}-\text{R}^{9'}$,

f) $-\text{SO}_2\text{R}^{9'}$, wherein

$\text{R}^{6'}$ and $\text{R}^{7'}$ may be joined in a ring, and

$\text{R}^{7'}$ and $\text{R}^{8'}$ may be joined in a ring;

$\text{R}^{9'}$ is C_{1-4} alkyl or aralkyl;


a pharmaceutically acceptable salt thereof.

Claim 8 (previously presented): The compound (2S)-2-(2-methoxy-ethyl)-1-((cis)-3-sulfanyl-pyrrolidin-2-ylmethyl)-4-naphthoyl-piperazine or a pharmaceutically acceptable salt thereof.

Claim 9 (previously presented): A pharmaceutical composition which comprises a compound according to claim 7 or 8 and a pharmaceutically-acceptable carrier.

Claims 10-12 (**cancelled**).

Claim 13 (previously presented): A process for preparing compounds of the Formula B as defined in claim 7 which comprises deprotecting a compound of Formula VI:



Formula VI

wherein X^8 represents the right hand side of the Formula B as defined in claim 7, Pr^1 is H or an amino protecting group, Pr^2 is H or a thio protecting group and any functional groups in X^8 are optionally protected with the proviso that there is at least one protecting group and optionally, if desired, converting the product thus obtained into a pharmaceutically-acceptable salt thereof.

Claims 14-17 (**cancelled**).

Claim 18 (**previously presented**): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is carcinoma of the bladder, breast, colon, kidney, liver, lung, ovary, pancreas, stomach, cervix, thyroid or skin.

Claim 19 (**previously presented**): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a hematopoietic tumor of lymphoid lineage selected from acute lymphocytic leukaemia, B-cell lymphoma and Burkett's lymphoma.

Claim 20 (**previously presented**): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a hematopoietic tumor of myeloid lineage selected from acute or chronic myelogenous leukemias and promyelocytic leukaemia.

Claim 21 (**previously presented**): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a tumor of mesenchymal origin selected from fibrosarcoma and rhabdomyosarcoma.

Claim 22 (**previously presented**): A method of treating a disease or medical condition mediated through farnesylation of CAAX-containing proteins which comprises

administering to a warm-blooded animal an effective amount of a compound according to claim 7 or 8, wherein said disease or medical condition is a tumor selected from melanoma, seminoma, teratocarcinoma, neuroblastoma and glioma.